Insmed Incorporated
$141.33-$3.13 (-2.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $22.7B
- P/E
- -17.8x
- Revenue
- $606.4M
- Net margin
- -210.5%
- ROCE
- -55.4%
Price chart
Technical chartScreen technicals →-29.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +47.7%
- 3M
- +13.0%
- 6M
- +31.0%
- 1Y
- -29.2%
- 5Y
- Hidden
- This period includes a one-day price step on 28 May 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$3.13 (-2.2%) from $144 to $141 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in INSM, bought on each weekday since 2021.
News & filings
What Insmed Incorporated filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 1.3 billion US dollars in fiscal 2025.
Strengths (1)
- The company carries almost no debt: debt to equity of 0.04.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Read moreShow less
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
- Sector
- Healthcare
- Shares outstanding
- 214.3M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $22.7B
- P/E
- -17.8x
- P/B
- 30.8x
- EV / Sales
- 36.7x
- P/S
- 37.5x
- 52-week high
- $211.41
- 52-week low
- $91.88
Profitability
- Operating margin
- -164.0%
- Net margin
- -210.5%
- EBITDA margin
- -194.2%
- ROE
- -172.8%
- ROCE
- -55.4%
- ROA
- -56.4%
- Asset turnover
- 0.27
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $606.4M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 66.7%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 35.2%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 39.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$967.6M
Solvency
- Current ratio
- 3.83
- Debt / Equity
- 0.04
- Debt / Assets
- 0.01
- CFO / Net profit
- 0.73
- Cash / Market cap
- 2.2%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $606.4M |
| Cost of revenue | $122.9M |
| Gross profit | $483.5M |
| Operating expenses | $1.5B |
| Research and development | $771.1M |
| Selling, general and administrative | $701.2M |
| Operating income | -$994.8M |
| Interest and other | -$277.0M |
| Pretax income | -$1.3B |
| Tax and other | $5.0M |
| Net income | -$1.3B |
Revenue and net profit
Revenue grew 66.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $245.4M | -$481.5M |
| FY2023 | $305.2M | -$749.6M |
| FY2024 | $363.7M | -$913.8M |
| FY2025 | $606.4M | -$1.3B |
Cash flows
FY2025: -$935.0M from operations, -$967.6M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$400.4M | -$410.3M |
| FY2023 | -$536.2M | -$549.5M |
| FY2024 | -$683.9M | -$705.8M |
| FY2025 | -$935.0M | -$967.6M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $606.4M+66.7%1Y
- EBITDA
- -$1.2B
- Net profit
- -$1.3B
- Cash from operations
- -$935.0M
- Free cash flow
- -$967.6M
- Revenue CAGR, 3Y
- 35.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $606.4M | -$1.2B | -$1.3B | -$967.6M | -172.8% | +66.7% | +39.7% |
Monthly returns
Month-by-month returns of INSM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $2.3B |
| Current assets | $1.8B |
| Non-current assets | $470.4M |
| Liabilities | $1.5B |
| Current liabilities | $468.9M |
| Non-current liabilities | $1.1B |
| Equity | $739.0M |
| Paid-in capital | $6.4B |
| Retained earnings | -$5.6B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; INSM highlighted.
P/E against peers
INSM has no positive P/E; the peer median is 24.4x.
Not shown (no positive earnings and no EV / Sales): Insmed Incorporated, Moderna, Inc., Viatris Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Insmed IncorporatedINSMthis company | $22.7B | -17.8x | 30.8x | -172.8% | — |
| Mettler-Toledo International Inc.MTD | $23.9B | 27.4x | — | -3676.8% | 20.9x |
| West Pharmaceutical Services, Inc.WST | $22.4B | 45.4x | 7.1x | 15.5% | 28.4x |
| Quest Diagnostics IncorporatedDGX | $21.7B | 21.9x | 3.0x | 13.8% | 12.9x |
| Labcorp Holdings Inc.LH | $21.4B | 24.4x | 2.5x | 10.2% | 13.6x |
| STERIS plcSTE | $20.7B | 26.5x | 2.9x | 10.9% | 14.0x |
| Moderna, Inc.MRNA | $20.5B | -7.3x | 2.4x | -32.6% | -7.5x |
| Incyte CorporationINCY | $20.2B | 15.7x | 3.9x | 24.9% | 9.8x |
| Viatris Inc.VTRS | $18.5B | — | 1.3x | -23.9% | — |
| Peer median | — | 24.4x | 2.9x | 10.5% | 13.6x |
Year-to-date ROI
INSM since 1 January, against earlier years.
Historical volatility
INSM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -194.9% |
| FY2023 | -223.1% |
| FY2024 | -216.3% |
| FY2025 | -164.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $606.4M |
| Cost of revenueCost Of Revenue | $122.9M |
| Gross profitGross Profit | $483.5M |
| Operating expensesOperating Expense | $1.5B |
| Research and developmentResearch And Development | $771.1M |
| Selling, general and administrativeSelling General And Administration | $701.2M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $6.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $6.0M |
| Amortization | $6.0M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $6.0M |
| Total expensesTotal Expenses | $1.6B |
| Operating incomeOperating Income | -$994.8M |
| Interest and other | |
| Pretax incomePretax Income | -$1.3B |
| TaxTax Provision | $5.0M |
| Net incomeNet Income | -$1.3B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $2.3B |
| Current assetsCurrent Assets | $1.8B |
| Non-current assetsTotal Non Current Assets | $470.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $1.5B |
| Current liabilitiesCurrent Liabilities | $468.9M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $1.1B |
| EquityTotal Equity Gross Minority Interest | $739.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$935.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$935.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$1.3B |
| Depreciation and amortisationDepreciation And Amortization | $16.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $16.4M |
| Depreciation | $10.4M |
| Amortization cash flowAmortization Cash Flow | $6.0M |
| Amortization of intangiblesAmortization Of Intangibles | $6.0M |
| Amortization of securitiesAmortization Of Securities | -$38.4M |
| Stock-based compensationStock Based Compensation | $152.7M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Change in working capitalChange In Working Capital | -$80.3M |
| Other non-cash itemsOther Non Cash Items | $291.3M |
| Investing cash flowInvesting Cash Flow | -$64.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$64.6M |
| Capital expenditureCapital Expenditure | -$32.6M |
| Purchase of PP&EPurchase Of PPE | -$32.6M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$32.6M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | -$2.1B |
| Sale of investmentsSale Of Investment | $2.1B |
| Net investment purchases and salesNet Investment Purchase And Sale | -$2.0M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | -$30.0M |
| Financing cash flowFinancing Cash Flow | $954.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $954.1M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$4.9M |
| Net debt issuedNet Issuance Payments Of Debt | -$4.9M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$4.9M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$4.9M |
| Shares issuedIssuance Of Capital Stock | $823.3M |
| Common stock issuedCommon Stock Issuance | $823.3M |
| Net common stock issuedNet Common Stock Issuance | $823.3M |
| Stock options exercisedProceeds From Stock Option Exercised | $135.7M |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | -$45.5M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 93.0% |
| Cash at the start of the yearBeginning Cash Position | $555.0M |
| Cash at the end of the yearEnd Cash Position | $510.4M |
| Free cash flowFree Cash Flow | -$967.6M |
| Supplemental |
Learn while you research
Academy chapters picked for Insmed Incorporated and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing67% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read